News | August 09, 2022
Briefs: Zydus Lifesciences and Kimia Biosciences
The inspection concluded with four Form 483 observations. None of the observations were related to data integrity.
The inspection concluded with four Form 483 observations. None of the observations were related to data integrity.
The company is focused on therapies such as skinceuticals, gastroenterology, neuropsychiatry, cardiac diabetes care etc.
Suven Life Sciences has reported total income of Rs. 3.97 crores during the period ended June 30, 2022
The company has reported total income of Rs. 186.97 crores during the period ended June 30, 2022.
Strand Life Sciences has sequenced a total of 12800 samples from July, 2021 to June, 2022, and identified more than a 100 lineages circulating in Bengaluru
Advancing to IND-enabling studies with multiple drug candidates
CEPI will provide seed funding of up to US$2.5 million to Codiak BioSciences.
An interim analysis of this data shows no significant safety issues and a 91% seroconversion rate at Day 56.
The company is strategically expanding its product portfolio with a pipeline of new products that will form a strong foundation for future growth.
The capacity addition in Suwa is part of Saint-Gobain Life Sciences ongoing investment plan to globally expand production capacity for its products and services used throughout the bioprocessing industry
Subscribe To Our Newsletter & Stay Updated
